ViroLogik GmbH, a biopharma-ceutical company focused on the development of therapies for the treatment of viral infectious diseases, recently received a 1.466 million Euro grant from the "KMU innovative Biotechnology BioChance" Program of the Federal Ministry for Education and Research (BMBF).
Research & Development projects from small and medium-sized companies in the biotechnological area are supported by this program. The grant will be employed for the completion of the preclinical development of an own proteasome inhibitor for the treatment of patients with chronic hepatitis C virus (HCV) infection, and the preparation of a clinical phase Ia study. Start of the phase I study is planned for the first quarter 2011.
"The BMBF grant supports the strategic orientation of our company to continue the development of our propriatary proteasome inhibitor treatment. Therefore, our Research & Development results and the work done since the company foundation in March 2006 have once again been sustainably convincing. We are confident of being able to test our proprietary proteasome inhibitor VL-01 first in humans already in 2011 and in this way be able to make our contribution to combating viral diseases," emphasises Karl Appelmann, Managing Director of ViroLogik GmbH, in response to the BioChance Programme grant.
ViroLogik develops and tests novel medications for the treatment of virus infection diseases with the main focus on Hepatitis C, HIV/AIDS and Influenza. The approach consists of preventing the replication of the viruses by inhibition of factors of the host cell. This approach, therefore, possibly represents a way to develop medications without the risk of resistance development.
ViroLogik employs target structures of the host cell, which have already been proven in the clinic and market. In this way the risk for clinical development and market approval is minimized. Extensive partnerships with leading research institutes, hospitals and industrial partners assure access to the necessary expertise and resources. ViroLogik possesses its own patent portfolio and its own proprietary substance, and is focused on the development of a medication to treat patients with chronic hepatitis C virus infection.
ViroLogik GmbH
